INT MEDICAL (01501) has released its interim results for the six months ended June 30, 2026, reporting a revenue of RMB 596 million, representing a year-on-year increase of 29.28%.

The company recorded a profit attributable to equity shareholders of RMB 110 million, up 11.97% compared to the same period last year, with earnings per share of RMB 0.54.

The revenue growth was primarily driven by acquisitions and mergers that filled product gaps and established a comprehensive product portfolio matrix, as well as the realization of synergies through channel reuse and supply chain integration, which boosted sales of interventional medical devices.